| 1 |
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.
DOI
ScienceOn
|
| 2 |
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
DOI
ScienceOn
|
| 3 |
Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011;18:351-8.
DOI
ScienceOn
|
| 4 |
Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
DOI
ScienceOn
|
| 5 |
Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
DOI
ScienceOn
|
| 6 |
Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203:325-30.
DOI
ScienceOn
|
| 7 |
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
DOI
ScienceOn
|
| 8 |
Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62.
DOI
ScienceOn
|
| 9 |
Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-9.
DOI
ScienceOn
|
| 10 |
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
DOI
ScienceOn
|
| 11 |
Peters SA, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med 2010;268:155-61.
DOI
ScienceOn
|
| 12 |
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
DOI
ScienceOn
|
| 13 |
Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline highsensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010; 106:204-9.
DOI
ScienceOn
|
| 14 |
Kim YR, Park JH, Lee HJ, Pyun WB, Park SH. The effect of doubling the statin dose on pro-inflammatory cytokine in patients with triple-vessel coronary artery disease. Korean Circ J 2012;42:595-9.
DOI
|
| 15 |
Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8.
DOI
ScienceOn
|
| 16 |
Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373: 1175-82.
DOI
ScienceOn
|
webmaster
